Phase 1 Randomized Double-Blind Placebo-Controlled Study of AK1967 (Procizumab) Safety, Tolerability, and Pharmacokinetics in Healthy Male Volunteers

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics**/**pharmacodynamics** of escalating single intravenous doses of AK1967 (Procizumab) in healthy male volunteers. This is clinically relevant as it aims to establish the foundational safety profile and dosing parameters of Procizumab, which could potentially be used in the treatment of **circulatory shock**. Understanding these parameters is crucial for the development of effective therapeutic interventions for this condition.

The clinical trial focuses on **circulatory shock** and involves a study population exclusively composed of male participants. The age range of the participants is categorized under code "3," which typically represents adults, although specific age details are not provided. The sponsor has not disclosed the total number of participants involved in the trial. The selection process for the trial population and any relevant lifestyle considerations, such as diet or physical activity, have not been specified. The trial does not include a vulnerable population, and no information regarding key inclusion or exclusion criteria has been provided by the sponsor.

The clinical trial is designed as a **randomized**, **double-blind**, **placebo-controlled** phase 1 study to evaluate the safety, tolerability, and pharmacokinetics/dynamics of escalating single intravenous doses of AK1967 (Procizumab) in healthy male volunteers. The study targets the condition of **circulatory shock**. The trial is scheduled to commence on January 15, 2024, with an estimated completion date of April 15, 2024, indicating a total duration of approximately three months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational product or a placebo. The study will include multiple follow-up visits to monitor safety and collect pharmacokinetic and pharmacodynamic data. These visits are crucial for assessing the primary and secondary endpoints of the trial. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to ensure participant safety and gather comprehensive data for analysis.

The expected length of participant involvement is the entire duration of the trial, from the initial screening to the end-of-study visit. However, conditions such as adverse events, non-compliance with study procedures, or withdrawal of consent may lead to early termination from the study. Participants will be closely monitored throughout the trial to ensure adherence to the protocol and to address any safety concerns promptly.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Due to the lack of available data, further information on drug administration, dosing schedules, and participant compliance monitoring cannot be described. The absence of these details limits the ability to provide a comprehensive overview of the treatments involved in the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is January 15, 2024, with an anticipated end date of April 15, 2024. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. The trial will likely employ standardized methods for data collection and analysis, consistent with Phase 1 objectives, to ensure reliable and valid results. The absence of detailed endpoints suggests a focus on exploratory outcomes, which may include initial observations of therapeutic effects or biomarker changes. The trial's design will adhere to rigorous scientific standards to evaluate the investigational product's potential efficacy in a controlled setting.